IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / February 6, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (NASDAQ: TGTX). Investors, who purchased or otherwise acquired TG Therapeutics shares between September 15, 2014 and October 12, 2016 inclusive (the “Class Period”), are encouraged to contact the firm prior to the March 7, 2017 lead plaintiff motion deadline.

If you purchased shares of TG Therapeutics, Inc. during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

According to the Complaint, on September 17, 2015, TG Therapeutics announced it had been contacted by the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment on the design of a Phase 3 clinical trial for TG-1101 and TGR-1202.

This Phase 3 trial, known as the GENUINE trial, was designed to show that TG-1101 could demonstrate an increase in the response rate and progression-free survival (“PFS”) in 330 existing patients with certain cancer cell mutations.

The Complaint states that TG Therapeutics officials concealed important information concerning the Phase 3 trial, suggesting to shareholders that it is the “best-in-class” treatment, that it will be “successful” and that it will “offer patients a novel chemo-free treatment option.” Furthermore, TG Therapeutics did not enforce a proper vetting tool in the GENUINE enrolling locations and did not enroll patients at the required rate for the study to be successfully completed. Finally, the trial failed to attract 330 patients, contrary to the Company’s statements.

On October 13, 2016, TG Therapeutics issued a statement disclosing it had filed an amended GENUINE Phase 3 trial protocol with the FDA. That same day, TheStreet released an article suggesting that TG Therapeutics has a long history of poor management. The article also disclosed that the company stopped the intended enrollment for the GENUINE trial by a third, removed crucial efficacy endpoints, and generally exposed the company to greater risk. When this information was revealed to the public, TG Therapeutics’ stock declined almost 27% on October 17, 2016, causing investors harm.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

If you wish to learn more about this lawsuit, at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 454369